Lv11
40 积分 2023-10-21 加入
Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial)
1小时前
求助中
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
15天前
已完结
Radiation-Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning Regimens
2个月前
已完结
Comparison of Radiation-Induced Secondary Cancer Occurrence Rates for Major Organs Between Total Body Irradiation and Total Marrow Irradiation
2个月前
已完结
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
3个月前
已完结
Total body irradiation in allogeneic bone marrow transplantation conditioning regimens: A review
3个月前
已完结
Total marrow lymphoid irradiation and cyclophosphamide is associated with low toxicity and good outcomes in patients undergoing hematopoietic stem cell transplantation for acute lymphoblastic leukemia and chronic myeloid leukemia in lymphoid blast crises – A phase I study
3个月前
已完结
Comparing the outcomes between TMLI and non-TMLI conditioning regimens for adult high-risk acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a single-center experience
3个月前
已完结
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
4个月前
已完结
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
